Doctor insights on:
Hepatitis A And Vaqta
Hep A and B vaccines: Almost all children in this current generation are immunized against both hep a and b in the first 2 years of life. It is still recommended to have both vaccines. Food is often contaminated so the hep a vaccine should offer protection. Healthcare workers are required to receive the hep b vax. Anyone can still have the vaccine to protect themselves from partners who may have the disease. ...Read moreSee 1 more doctor answer
Sir please tell me if a person with chronic hepatitis b is treated with medicine and regular check up by a doctor has a chance of liver complication?
Yes: I'm sorry there's always a chance of complications . ...Read more
I volunteer in hospitals with a therapy dog ihave annual TB tests and a flu shot but was wondering whether to get hep a and b?
Liver biopsy: Liver cancer is a serious cancer and needs to be treated quickly and aggressively. The prognosis depends on a number of factors, including the size, precise location and local/distant spread of the tumor. The oncologist would be able to provide more precise information given the specific details of a case. ...Read moreSee 1 more doctor answer
??? what ???: The vaccines do not "treat" any illness.If taken before exposure they may help someone build personal immunity and prevent a viral disease from starting. At this point we have very few medications that have anti-viral properties. Bacteria,fortunately, are more amenable to available drugs. ...Read more
Can you get hep c drinking out of someone with hep c glass of water thinking it was your own and is hep c curable?
Take it easy: Hepatitis-c infection is spread through sharing needles, receiving blood products, sexual contact; etc. It does not spread through digesting food or water. Good luck ! ...Read more
If parts of a liver is removed from a cirrhosis patient who was a Hep B carrier but is now 100% Hep B immune, will "normal" liver tissue be regrown?
My children had to get vaccines for hepatitis A and B. Why isn't there a vaccine for hepatitis C?
Efforts to develop a hepatitis C vaccine started more than 20 years ago, when the hepatitis C virus was identified: Since then, researchers have studied several potential vaccines in animals. Only one vaccine is currently being tested in people. Completion of that vaccine trial is expected in 2016. If it shows that the vaccine prevents chronic hepatitis C, larger trials will still be necessary to verify this effect and determine the best way to deploy the vaccine. Progress has been slow for a number of reasons, including: The hepatitis C virus is more variable than are the viruses that cause hepatitis A and hepatitis B. For starters, hepatitis C virus occurs in at least six genetically distinct forms (genotypes), with multiple subtypes. About 50 subtypes have been identified. The most common hepatitis C virus genotypes vary by geography. Hepatitis C type 1 virus is most common in the United States and Europe. Type 3 is most common in India, the Far East and Australia. And type 4 is most common in Africa and the Middle East. A global vaccine would have to protect against all these variants of the virus. Hepatitis C virus can infect chimpanzees, and the infection in chimpanzees is similar to that in adults. Ethical and cost concerns, however, limit medical research with these animals. In the past decade, genetically modified mice with grafted human liver cells have proved to be valuable models for study of hepatitis C infection. The only way to find out if a vaccine prevents an infection is to test it in people who are at risk. In developed countries, those at highest risk of hepatitis C infection are people who use needles to inject street drugs. Because injection drug users tend to avoid health care and be difficult to keep in touch with, it can be expensive and time-consuming to enroll, treat and follow them. A much larger population is at risk of hepatitis C in developing countries, where infection continues to spread via blood transfusions and reuse of supplies in hospitals. The same thing that causes rising rates of infection in developing countries — lack of health care facilities and staff — also makes vaccine trials extremely difficult. After you've had hepatitis A or hepatitis B, your immune system "remembers" the virus and keeps you from getting infected again. The hepatitis A and B vaccines work by provoking this protective memory of the viruses without causing illness. Hepatitis C infection is different. It rarely causes serious problems until you've been infected — often unknowingly — for many years. During those years, the virus escapes the body's immune defenses, which normally limit the course of infection and protect against reinfection. This means the types of vaccines developed for hepatitis A and hepatitis B viruses won't work against hepatitis C virus. Clues to an approach that might work have come from studies of the 30 percent of people whose immune systems get rid of the hepatitis C virus during the acute stage of infection — roughly the first six months after exposure to the virus. So far, however, researchers haven't found out exactly what immune system product or variation protects these people. Nor do they know exactly how this protective factor stops the virus before it becomes chronic. Answers to these questions may emerge in the next few years, fueling faster progress in hepatitis C vaccine development. ...Read more